New organ, old body — how to avoid 'tissue rejection' in private credit restructurings

Listen to this episode from Cloud 9fin on Spotify. Generally speaking, lenders don’t lend money to companies with the intention of ending up as equity owners. But things don’t always go to plan. And anyone who’s been there can tell you that the hard truth for certain companies is that no plan could have ever saved it — or as Jon Weber would say: “If the baby’s ugly, the baby’s ugly.”In this week’s episode of Cloud 9fin, senior private credit reporter Shubham Saharan sits down with Jon Weber and Gisele Everett of restructuring advisory Jon F Weber & Co, to talk about some of the hard truths they confront in their work. Among them, is how to avoid “tissue rejection,” to borrow a term from the medical field, which can occur when integrating new owners into an existing company.They also discuss a recent article that Jon and Gisele co-authored in the Journal of Corporate Renewal.Have any feedback for us? Send us a note at [email protected].